Category - Developments

Developments

Hepion reports CRV431 may reduce risk of NASH-associated ischemic stroke

Hepion Pharmaceuticals (NASDAQ:HEPA) reported results from a translational research study in which its lead drug candidate, CRV431, decreased formation of procoagulant platelets. The company noted that patients with...

December 2, 2020

Developments

Aeglea BioTherapeutics gets FDA rare pediatric disease designation for homocystinuria

Aeglea BioTherapeutics’ (NASDAQ:AGLE) ACN00177 received FDA rare pediatric disease designation for the treatment homocystinuria. Homocystinuria is a serious metabolic disorder characterized by elevated plasma...

December 1, 2020

Developments

Bellerophon enrolls first patient in Phase 3 INOpulse study

Bellerophon Therapeutics (NASDAQ:BLPH) enrolled the first patient in its Phase 3 REBUILD study evaluating INOpulse, a pulsed nitric oxide system, for the treatment of fibrotic interstitial lung disease (fILD). The study...

December 1, 2020

Developments

Athira initiates dosing in Phase 2 Alzheimer’s disease study

Athira Pharma (NASDAQ:ATHA) initiated patient dosing in its ACT-AD Phase 2 trial evaluating ATH-1017 in patients with mild-to-moderate Alzheimer’s disease (AD). ATH-1017 is a small molecule designed to regenerate...

December 1, 2020

Developments

Moleculin Biotech gets FDA rare pediatric disease designation for three indications

Moleculin Biotech’s (NASDAQ:MBRX) WP1066 received FDA rare pediatric disease indication for the treatment of diffuse intrinsic pontine glioma (DIPG), medulloblastoma and atypical teratoid rhabdoid tumor. WP1066 is an...

December 1, 2020

Developments

Ovid Therapeutics’ OV101 fails Phase 3 Angelman syndrome trial

Ovid Therapeutics (NASDAQ: OVID) reported that its Phase 3 NEPTUNE trial evaluating OV101 for the treatment of Angelman syndrome failed to meet its primary endpoint. Angelman syndrome is a rare genetic disorder that...

December 1, 2020

Developments

Profound Medical gets FDA humanitarian device exemption approval for Sonalleve

Profound Medical’s (NASDAQ:PROF; TSX:PRN) Sonalleve received FDA humanitarian device exemption (HDE) approval for the treatment of osteoid osteoma. Osteoid osteoma is a non-cancerous bone tumor that occurs most often in...

November 30, 2020

Developments

BlueRock co-founder, Gordon Keller, receives 2020 Bloom Burton award

Gordon Keller, Ph.D., co-founder of BlueRock Therapeutics, received the 2020 Bloom Burton award, which honors an individual who has made the most significant contribution to Canada’s innovative healthcare industry...

November 26, 2020

Developments

Urovant Sciences vibegron fails Phase 2a IBS trial

Urovant Sciences (NASDAQ:UROV) reported disappointing topline results from its Phase 2b trial of vibegron for the treatment of abdominal pain due to irritable bowel syndrome (IBS) in women. The study failed to meet its...

November 25, 2020

Developments

KA Imaging launches subscription model for portable X-ray device

Closely-held KA Imaging introduced a new hardware subscription model to help U.S. and Canadian hospitals acquire Reveal 35C, the company’s portable X-ray device, during the pandemic. Reveal 35C is a portable, single...

November 24, 2020

Category - Developments

Hepion reports CRV431 may reduce risk of NASH-associated ischemic stroke

Aeglea BioTherapeutics gets FDA rare pediatric disease designation for homocystinuria

Bellerophon enrolls first patient in Phase 3 INOpulse study

Athira initiates dosing in Phase 2 Alzheimer’s disease study

Moleculin Biotech gets FDA rare pediatric disease designation for three indications

Ovid Therapeutics’ OV101 fails Phase 3 Angelman syndrome trial

Profound Medical gets FDA humanitarian device exemption approval for Sonalleve

BlueRock co-founder, Gordon Keller, receives 2020 Bloom Burton award

Urovant Sciences vibegron fails Phase 2a IBS trial

KA Imaging launches subscription model for portable X-ray device

General

More